PROSTVAC, an active immunotherapy vaccine, can induce the immune response of tumor-infiltrating T-cells by targeting prostate-specific antigen (PSA) and demonstrates high potency and low adverse effects against PCa patients with low disease burden and indolent disease (Gulley et al., 2019). The gene discussed is KLK3; the disease is posterior cortical atrophy.